Photopheresis for early diffuse scleroderma
Part of Skin clinical trials.
This trial tests a treatment called extracorporeal photopheresis (ECP) for people with early diffuse systemic sclerosis (scleroderma). ECP is a procedure where your blood is treated with light and a medication, then returned to your body, and it may help reduce skin thickening and other symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older
- You must have a confirmed diagnosis of systemic sclerosis (scleroderma), specifically the diffuse type
- You must be within 5 years of your first non-Raynaud's symptom, or have signs of active disease like high skin score, friction rubs, or certain lung changes
- You must not have severe lung, heart, or other major health problems that would make the treatment risky
- You must not be on more than two immunosuppressants at the start
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This trial tests a new drug called telitacicept for people with recently diagnosed, rapidly progressing systemic sclerosis (scleroderma). It aims to see if the drug can slow down skin thickening and other symptoms.
This trial tests an investigational drug called MTX-474 for people with diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The study aims to see if it can help slow or improve skin thickening and other symptoms.
This trial tests a new type of cell therapy made from a patient's own white blood cells (called lymphocytes) that are designed to help control the immune system. The goal is to reduce inflammation and symptoms in people with hard-to-treat rheumatoid arthritis or a severe form of scleroderma (dcSSc).
This trial tests a treatment called photopheresis to treat early-stage mycosis fungoides, a type of skin lymphoma. It may help reduce or control skin patches or plaques that have not responded well to standard treatments.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
Hear when a new Diffuse Cutaneous Systemic Sclerosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.